Is Roche undervalued?

I'm curious, have you taken a closer look at Roche's financials and market positioning? Considering their industry standing, diverse product portfolio, and recent earnings reports, wouldn't you say that their current valuation seems a bit low compared to their peers? Perhaps a deeper dive into their financial health, growth potential, and competitive advantages could shed some light on whether Roche is indeed undervalued or if there are other factors at play.